Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin

Next Previous
Trial Profile

Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2018

At a glance

  • Drugs Botulinum-antitoxin (Primary)
  • Indications Botulism
  • Focus Adverse reactions
  • Sponsors Cangene Corporation

    • Most Recent Events

    • 24 Jan 2018 Status changed from recruiting to completed.
    • 04 Apr 2016 Planned End Date changed from 1 Apr 2018 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 04 Apr 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top